retatrutide diarrhea management Unapproved weight loss drug causes extreme side effects Retatrutide and Bowel Changes: Causes,

Full-dose, dual-hormone GLP-1 and GIP therapy, provider-led and built for women

This article explores the details of Kaisers coverage for weight loss drugs, offering readers vital insights and practical steps to assess their eligibility

Unlike traditional GLP1 agonists such as semaglutide or dual agonists like tirzepatide, retatrutides tripleagonist mechanism aims not only to reduce appetite and enhance insulin secretion but also to increase energy expenditure and influence lipid metabolism more profoundly, potentially offering greater adipose tissue reduction and metabolic improvements

The work of Lebrun et al now adds an important piece to this puzzle by describing a critical and previously unrecognized role for the gut-derived hormone glucagon-like-peptide 1 (GLP-1) in the regulation of intestinal inflammation

Forecasting postbariatric hypoglycaemia in patients after Roux-en-Y gastric bypass using model-based algorithms fed by continuous glucose monitoring data: a proof-of-concept study